SPÓŁKA AKCYJNA
Progresja
Progresja Spółka Akcyjna
KRS: 0000713254NIP: 6342825787REGON: 243504927Share capital: 500.5 K PLN
Research and development72.10.ZScientific research and development
UL. ŻELAZNA, 9, 40-851, KATOWICE, POLSKAActive
SPÓŁKA AKCYJNA
Progresja
Progresja Spółka Akcyjna
SPÓŁKA AKCYJNA
Progresja Spółka Akcyjna
Progresja Spółka Akcyjna (KRS 0000713254, NIP 6342825787) is a Polish company, headquartered in Katowice, Śląskie voivodeship. PROGRESJA operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since January 17, 2018.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Main activity
72.10.ZScientific research and development
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
WWW.PROGRESJA.COFounded
January 17, 2018
8 years in operation
Legal form
SPÓŁKA AKCYJNA
Registry: RejP
Headquarters
KATOWICE
ŚLĄSKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
500.5 K PLN
Shareholders
N/A
Board
4 people
Sup. board: 3
Filed years
N/A
Registry entries
36
latest: June 19, 2026
No KPI data - financial statements and valuation are unavailable for this company.
Rate business credibility - Progresja.
No ratings
News
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
Latest reporting year
2025
Available years
8
Filing entries
0
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
PROGRESJA's board has 4 members.
Public-procurement proceedings in which Progresja appears as contractor or contracting authority - total contract value, signing dates, procedures and links to the official notices.
3 most recent proceedings
Realizacja prac badawczo-aplikacyjnych z wykorzystaniem systemu wytwarzania przyrostowego Renishaw AM400/AM250 dla materiału AZ91E
Dostawa: System do wytwarzania przyrostowego elementów metalowych technologiami SLS/SLM
20 historical registry entries for Progresja
Board change
KA.VIII NS-REJ.KRS/27724/24/478
Change in Section 1 (basic data)
KA.VIII NS-REJ.KRS/36656/24/78
Change in Section 1 (basic data)
KA.VIII NS-REJ.KRS/36656/24/78/ADE
Articles of association amended, Primary PKD code change, Secondary PKD code change
KA.VIII NS-REJ.KRS/7009/25/123
Filing documents submitted (3 documents)
Competing companies or those operating in the same market segment as Progresja (in Katowice, industry: Research and development).
KATOWICE· Research and development
Revenue 2024: 31.3 M PLN
KATOWICE· Research and development
Revenue 2024: 6.0 M PLN
PIEKARY ŚLĄSKIE· Research and development
Revenue 2024: 2.5 M PLN
KATOWICE· Research and development
Revenue 2024: 1.7 M PLN
KATOWICE· Research and development
Revenue 2024: 723.0 K PLN
KATOWICE· Research and development
Revenue 2024: 695.3 K PLN
